Over the past few years, the Group has moved from a pre-revenue R&D Group to a business with a commercialised product selling online and on the shelves at retailers with first meaningful revenues being generated.
Our strategy is to commercialise innovative and clinically proven products for the OTC sexual health market. We will then partner with leading consumer healthcare partners who are well resourced to commit significant marketing spend and expertise.
This strategy is aligned with the demographic changes of ageing populations, increasing prosperity and the expectation of people to lead a full and active life no matter their age.
With an innovative R&D team, we will look to fulfil the needs of the large, underserved OTC sexual health market.
We now report against our three strategic pillars:
- Address the growing needs within the OTC sexual health market
- Broaden the Company’s clinically proven product range leveraging its innovative and experienced R&D capability whilst being mindful of costs and focusing on ROI.
- Commit to delivering strong returns for shareholders, sustained profitability and financial discipline
Our priorities for 2025 are:
- Address – Obtain Eroxon® Intense regulatory approvals in USA, EU and UK to provide our commercial partners a product extension to Eroxon®.
- Broaden – Conduct Early Feasibility Study for WSD4000 product to refine the clinical methodology, optimise the efficacy and further inform the consumer experience of the product.
- Commit – Continue to launch Eroxon® in other markets and work with our partners in geographies where we have already launched to build brand awareness, sales and ultimately revenue and profits.